Companies: 10,795·Total market cap: $144.5T
Solid Biosciences Inc.

Solid Biosciences Inc.

SLDBNASDAQHealthcare● Active
$6.41
$-0.29(-4.33%)
Market Cap$499404382
P/E Ratio
52W High$8.866
52W Low$3.675
Overview

Solid Biosciences Inc. (SLDB) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

sldb · stock forecast · 21 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 21 Wall Street analysts in the past 3 months

SellBuy

Buy

21 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
16
Hold
5
Sell
0
Strong Sell
0
Total: 21 · Buy rate: 76.2%

12-Month Price Target

High

$18.00

Consensus

$17.00

+165.2% upside

Low

$16.00

Median: $17 · Last Close: $6.41

The Solid Biosciences Inc. (SLDB) analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month SLDB price target is $17.00, representing +165.2% upside from the current price of $6.41.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $17 (165.2%)

Consensus Target

$17.00

165.2% upside

High Target

$18

180.8%

Low Target

$16

149.6%

Current Price

$6.41

as of today

Based on analyst price targets, the SLDB stock price prediction for the next 12 months ranges from $16 to $18. The consensus SLDB price forecast of $17.00 implies 165.2% upside from the current price of $6.41.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$6.291.84%

1-day model range: $6.24–$6.34. Peak: $6.34 (-1.84%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$5-27.7%
2028$4-38.7%
2029$4-43.8%
2030$3-46.4%
2031-47.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%7%86%
1Buy
1Neutral
12Sell
RSI (14)48.7Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · SLDB · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$6.76SELL
MA 10$6.93SELL
MA 20$6.94SELL
MA 50$7.39SELL
MA 100$6.98SELL
MA 200$6.22BUY
Current $SLDB · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$6.74SELL
EMA 10$6.83SELL
EMA 20$6.95SELL
EMA 50$7.09SELL
EMA 100$6.88SELL
EMA 200$6.43SELL
Current $SLDB · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-06-03
Maintains
BuyBuy
Wedbush2026-05-18
Maintains
OutperformOutperform
Wedbush2026-05-13
Maintains
OutperformOutperform
Piper Sandler2026-05-13
Maintains
OverweightOverweight
JP Morgan2026-03-25
Maintains
OverweightOverweight
HC Wainwright & Co.2026-03-23
Maintains
BuyBuy
Needham2026-03-20
Maintains
BuyBuy
Chardan Capital2026-03-20
Maintains
BuyBuy
Wedbush2026-03-12
Maintains
OutperformOutperform
Chardan Capital2026-03-12
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Solid Biosciences Inc. (SLDB) stock. Of the recent 94 rating actions, 9 were upgrades and 6 were downgrades. 21 analysts currently cover SLDB.

Analyst Recommendation Trends

Buy ratings413
Hold ratings00
Sell ratings00

SLDB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$4M

↓ 97.1% YoY

Revenue Next Year

$13M

↑ 261.4% YoY

EPS This Year

$-1.93

EPS Next Year

$-1.93

↓ 0.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast SLDB EPS of $-1.93 for the current fiscal year, based on estimates from 10 analysts. The SLDB revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The SLDB stock forecast is supported by two independent data sources: analyst consensus ratings from 21 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SLDB price target is $17.00 (+165.2% upside), with an analyst consensus of Buy.

The SLDB short-term stock prediction for tomorrow is $6.29 (-1.84%). The SLDB stock price prediction for 2027 estimates an average of $5. The SLDB stock prediction for 2030 projects a range of $3–$4.

Solid Biosciences Inc. trades on NASDAQ under the ticker SLDB. The SLDB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 76% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

SLDB forecast · 8 questions

According to 21 Wall Street analysts, the average 12-month SLDB price target is $17.00, with a high forecast of $18.00 and a low of $16.00. The median price target is shown in the chart above when available. This implies +165.2% potential upside from the current price of $6.41.

SLDB price targetWhat is SLDB price targetSLDB analyst price targetSLDB 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.